Department of Hematology of Anhui Provincial Hospital, Anhui Medical University, Hefei, Anhui, China.
Eur J Haematol. 2012 Jan;88(1):39-45. doi: 10.1111/j.1600-0609.2011.01709.x. Epub 2011 Nov 15.
Pre-engraftment syndrome (PES) after umbilical cord blood transplantation (CBT) remains poorly characterized, and the prognosis and appropriate management are unclear. Therefore, we retrospectively analyzed the incidence, risk factors, manifestations, and clinical outcomes of PES in CBT recipients, who had been treated for hematologic malignancies at our transplantation center. PES was defined as unexplained fever higher than 38.3°C that is not associated with documented infection and unresponsive to antimicrobial manipulations and/or unexplained erythematous skin rash occurring prior to neutrophil engraftment. A total of 81 patients (median 18 yr, range 3-48) received either myeloablative (n=72) or non-myeloablative (n=9) conditioning. Neutrophil engraftment was achieved in 69 of the 81 cases [86.2%, 95% confidence interval (CI)=78.9-94.1%], and the median time to more than 0.5 × 10(9) /L ANC was 19 d (range, 12-39). Fifty-one patients (63.0%) developed PES at a median of 7d (range 3-15) post-transplant: 46 patients had both rash and unexplained fever; one patient had unexplained fever alone; and four patients had rash only. Forty-seven patients (92.2%) received IV methylprednisolone (MP) at a median dose of 1 mg/kg (range 0.4-3). All patients treated with MP responded as evidenced by fever resolution combined with resolution of rash. All patients with PES had high serum levels of C-reactive protein (CRP), which were significantly reduced after effective steroid treatment. Univariate analysis identified myeloablative conditioning and younger age as significant risk factors for developing PES. Cumulative incidence of grade II-IV acute graft-versus-host disease (aGVHD) in the PES+ and PES- groups was 51.5% (95% CI=38.0-70.0%) and 17.0% (95% CI=6.9-41.7%), respectively. In a multivariate analysis, we found significantly increased risk of grade II-IV aGVHD among PES patients (P=0.041). However, PES was not associated with sustained donor engraftment, the day to neutrophil recovery, chronic graft-versus-host disease, transplant-related mortality at day 180, and overall survival. Despite of the inherent limitations of this small retrospective study, PES seemed to be common after CBT and associated with high incidence of aGVHD.
植入前综合征(PES)在脐带血移植(CBT)后仍表现不佳,其预后和适当的管理尚不清楚。因此,我们回顾性分析了在我们移植中心接受血液系统恶性肿瘤治疗的 CBT 受者中 PES 的发生率、危险因素、表现和临床结局。PES 被定义为在中性粒细胞植入前发生的不明原因的发热高于 38.3°C,与已记录的感染无关,对抗微生物处理无反应,和/或出现不明原因的红斑性皮疹。共有 81 例患者(中位年龄 18 岁,范围 3-48 岁)接受了清髓性(n=72)或非清髓性(n=9)预处理。81 例患者中有 69 例(86.2%,95%置信区间[CI]=78.9-94.1%)获得了中性粒细胞植入,中位时间为 19 天(范围 12-39)。51 例患者(63.0%)在移植后中位时间 7 天(范围 3-15)出现 PES:46 例患者既有皮疹又有不明原因的发热;1 例患者仅出现不明原因的发热;4 例患者仅出现皮疹。47 例患者(92.2%)接受了静脉注射甲基强的松龙(MP)治疗,中位剂量为 1mg/kg(范围 0.4-3)。所有接受 MP 治疗的患者均有反应,表现为发热消退,皮疹消退。所有 PES 患者的血清 C 反应蛋白(CRP)水平均较高,经有效类固醇治疗后显著降低。单因素分析发现,清髓性预处理和年龄较小是发生 PES 的显著危险因素。PES+和 PES-组中 2 级至 4 级急性移植物抗宿主病(aGVHD)的累积发生率分别为 51.5%(95%CI=38.0-70.0%)和 17.0%(95%CI=6.9-41.7%)。多因素分析发现,PES 患者发生 2 级至 4 级 aGVHD 的风险显著增加(P=0.041)。然而,PES 与供体持续植入、中性粒细胞恢复时间、慢性移植物抗宿主病、第 180 天移植相关死亡率和总生存率无关。尽管这项小型回顾性研究存在固有局限性,但 CBT 后似乎很常见 PES,且与 aGVHD 发生率高相关。